MetLife Investment Management LLC Has $229,000 Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

MetLife Investment Management LLC increased its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 43.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,393 shares of the company’s stock after purchasing an additional 27,028 shares during the period. MetLife Investment Management LLC’s holdings in ImmunityBio were worth $229,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Stephens Inc. AR bought a new position in shares of ImmunityBio in the 4th quarter valued at approximately $26,000. Cibc World Markets Corp bought a new position in shares of ImmunityBio in the fourth quarter valued at approximately $35,000. Virtu Financial LLC acquired a new stake in shares of ImmunityBio in the third quarter worth $51,000. Maia Wealth LLC bought a new stake in shares of ImmunityBio during the 4th quarter worth $37,000. Finally, Schechter Investment Advisors LLC acquired a new position in ImmunityBio in the 4th quarter valued at $38,000. 8.58% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on IBRX. BTIG Research initiated coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 target price for the company. HC Wainwright reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday. Finally, D. Boral Capital reiterated a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $12.19.

ImmunityBio Trading Up 10.6 %

Shares of IBRX stock opened at $2.09 on Friday. The company has a market capitalization of $1.84 billion, a P/E ratio of -2.27 and a beta of 0.33. ImmunityBio, Inc. has a 12 month low of $1.83 and a 12 month high of $9.16. The stock has a 50 day moving average of $2.70 and a two-hundred day moving average of $3.39.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. Sell-side analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.